Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00573404 · ClinicalTrials.gov registry record · Phase 1
Imatinib Mesylate and Sunitinib in Treating Patients With Gastrointestinal Stromal Tumors
A Phase 1 study, sponsored by Vanderbilt-Ingram Cancer Center.
- Terminated
- Registry status
- Phase 1
- Development phase
- 6
- Enrollment target
NCT00573404 is a Phase 1 study that was terminated before completion, run by Vanderbilt-Ingram Cancer Center. The registered enrollment target is 6 participants.
The verdict
NCT00573404, a Phase 1 study, was terminated before completion, sponsored by Vanderbilt-Ingram Cancer Center.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 6 participants
- Enrollment target
Study Summary
RATIONALE: Imatinib mesylate and sunitinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. PURPOSE: This phase I trial is studying the side effects and best dose of imatinib mesylate given together with sunitinib in treating patients with gastrointestinal stromal tumors.
Interventions
- DRUG imatinib mesylate
- OTHER pharmacological study
- DRUG sunitinib malate
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 6 participants |
| Start Date | 2007-07 |
| Est. Completion | 2011-03 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00573404
The ClinicalTrials.gov registry entry for NCT00573404 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 6 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Vanderbilt-Ingram Cancer Center, which has 189 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which imatinib mesylate is the first listed.
NCT00573404 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00573404 about?
NCT00573404 is a clinical study titled "Imatinib Mesylate and Sunitinib in Treating Patients With Gastrointestinal Stromal Tumors". RATIONALE: Imatinib mesylate and sunitinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. PURPOSE: This phase I trial is studying the side effects and best dose of imatinib mesylate given together with sunitinib in treating patients with gastrointestinal ...
What is the current status of trial NCT00573404?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 6 participants. The study started on 2007-07. Estimated completion is 2011-03.
What interventions are being tested in trial NCT00573404?
The interventions under investigation include: imatinib mesylate (DRUG), pharmacological study (OTHER), sunitinib malate (DRUG).
Who is sponsoring clinical trial NCT00573404?
This trial is sponsored by Vanderbilt-Ingram Cancer Center, which has 189 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.